3 results
To investigate the bleeding pattern and cycle control parameters of the transdermal contraceptive patch (material no. 80876395, FC Patch Low containing 0.55 mg EE and 2.1 mg GSD) in comparison to the EVRA patch (containing 0.6 mg EE and 6 mg NGMN).
The study aims to limit the use of anthracyclines and to reduce the dose of ATRA. Another aim is to stratify treatment by risk group: standard risk - WBC <10 x 109/l : high risk - WBC >=10 x 109/l. Furthermore this study aims to…
Main objective:To determine the bioequivalence of the hormones (ie, NGMN and EE) from the transdermal contraceptive patch using the newly sourced adhesive component N100 at EOSL as compared to the currently marketed EVRA patch using the adhesive…